Table 2.
Serum MIAT and Clinical Characteristic Correlations in BC Patients
| Variable | Total (%) | The Expression of MIAT | P |
|---|---|---|---|
| Age | 0.479 | ||
| < 50 | 41 (50.0%) | 1.68±0.75 | |
| ≥ 50 | 41 (50.0%) | 1.91±0.98 | |
| BMI | 0.217 | ||
| < 24 | 40 (48.8%) | 1.91±0.93 | |
| ≥ 24 | 42 (51.2%) | 1.68±0.82 | |
| Menopause | 0.160 | ||
| Pre | 45 (54.9%) | 1.61±0.67 | |
| Post | 37 (45.1%) | 1.98±1.01 | |
| TNM Stage | 0.032* | ||
| I–II | 64 (78.0%) | 1.88±0.62 | |
| III–IV | 18 (22.0%) | 2.26±0.94 | |
| Tumor size | 0.114 | ||
| <2cm | 16 (19.5%) | 1.70±0.76 | |
| ≥2cm | 66 (80.5%) | 2.08±1.02 | |
| Lymph node Metastasis | 0.028* | ||
| Yes | 45 (54.9%) | 2.11±0.88 | |
| No | 37 (45.1%) | 1.70±0.68 | |
| ER | 0.586 | ||
| + | 53 (64.6%) | 1.70±0.73 | |
| – | 29 (35.4%) | 1.85±0.90 | |
| PR | 0.249 | ||
| + | 47 (57.3%) | 1.72±0.81 | |
| – | 35 (42.7%) | 1.88±0.87 | |
| Her-2 | 0.642 | ||
| + | 70 (85.4%) | 2.00±0.78 | |
| - | 12 (14.6%) | 1.84±0.83 | |
| Ki-67 | 0.184 | ||
| ≤ 10% | 21 (25.7%) | 2.06±0.89 | |
| > 10% | 61 (74.4%) | 2.11±0.94 |
Note: *Significantly different.
Abbreviations: BMI, body mass index; ER, estrogen receptor; PR, progesterone receptor; Her-2, human epidermal growth factor receptor 2; Ki-67, proliferating antigen Ki67.